ORA 14th Annual MeetingMore
The ORA 2015 Annual Meeting was held May 22-24, 2015
- New Rheumatology Tools Now Available for Oscar Users! More information ....
Update on Naproxen Suspension
Naproxen suspension has been relisted on Ontario Drug Benefits plan
Triple therapy for RA now approved for EAP
The Exceptional Access Program has decided to accept failure of 3 months of standard triple therapy (MTX 20 mg qweekly, Sulfasalzine 2 gm/day and Plaquenil 400 mg daily) to access EAP-funded biologic drugs. Full details can be accessed here.
- View All News
Diamond: The Arthritis Society, Pfizer Canada Inc., Amgen Canada Inc., Janssen Inc., Celgene Inc., Bristol-Myers Squibb Canada, Roche Canada
Platinum: GlaxoSmithKline Inc., UCB Canada Inc., AstraZeneca Canada Inc., Abbvie., Takeda Canada Inc.